跳转至内容
Merck
CN
所有图片(1)

文件

A5159

Sigma-Aldrich

氨基蝶呤

Hybri-Max™, 50 ×, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

别名:

4-氨基-PGA, 4-氨基叶酸, N-[4-[[(2,4-二氨基-6-蝶啶)甲基]氨基]苯甲酰]-L-谷氨酸, （S）-2- {4 - [（2,4-二氨基胍-6-基）甲氨基]苯甲酰氨基}戊二酸

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C19H20N8O5
CAS号:
54-62-6
分子量:
440.41
Beilstein:
69045
EC 号:
200-209-9
UNSPSC代码:
12352205
PubChem化学物质编号:
24890950
NACRES:
NA.75

生物来源

synthetic

质量水平

200

等级

Hybri-Max™

无菌性

γ-irradiated

产品线

BioXtra

形式

lyophilized powder

浓度

50 ×

技术

cell culture | hybridoma: suitable

杂质

endotoxin, tested

溶解性

10 mL/vial, clear, red (in TC Medium)

ε (消光系数)

24,500 at 282 nm in 0.1 M NaOH at 1 M
25,700 at 261 nm in 0.1 M NaOH at 1 M
8,100 at 373 nm in 0.1 M NaOH at 1 M

运输

dry ice

储存温度

−20°C

SMILES字符串

Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1

InChI

1S/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/t12-/m0/s1

InChI key

TVZGACDUOSZQKY-LBPRGKRZSA-N

基因信息

human ... FPGS(2356)
mouse ... Fpgs(14287)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

用于杂交瘤细胞培养应用的氨基蝶呤浓缩物添加剂。

生化/生理作用

叶酸拮抗剂。氨基蝶呤是由叶酸转运蛋白运输至细胞内的。在细胞内，它被叶酰聚谷氨酸合酶转化为一种高分子量的聚谷氨酸盐代谢物，该产物又与二氢叶酸还原酶结合并抑制其活性。氨基蝶呤-聚谷氨酸盐经 γ-谷氨酰基水解酶作用发生细胞内降解。

联系

比甲氨喋呤更有效，但毒性也更强。

重悬

10mL 无菌细胞培养基可复原一小瓶本品。储备液足以制备 500mL 培养基。最终工作浓度：0.4μM 氨基蝶呤。

法律信息

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

相关产品

产品编号
说明
价格

象形图

Skull and crossbonesHealth hazard
GHS06,GHS08

警示用语：

Danger

危险分类

Acute Tox. 1 Oral - Eye Irrit. 2 - Muta. 2 - Repr. 1B - Skin Irrit. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Aleem Gangjee et al.
Journal of medicinal chemistry, 48(16), 5329-5336 (2005-08-05)
We report, for the first time, the biological activities of four-carbon-atom bridged classical antifolates on dihydrofolate reductase (DHFR), thymidylate synthase (TS), and folylpolyglutamate synthetase (FPGS) as well as antitumor activity. Extension of the bridge homologation studies of classical two-carbon bridged
M Del Campo et al.
Teratology, 60(1), 10-12 (1999-07-21)
Maternal exposures to aminopterin and methotrexate have been associated with a pattern of malformation which includes prenatal-onset growth deficiency, severe lack of ossification of the calvarium, hypoplastic supraorbital ridges, small, low-set ears, micrognathia, and limb abnormalities. We report on a
A Rosowsky
Current medicinal chemistry, 6(4), 329-352 (1999-04-02)
Nonpolyglutamatable antifolates are potentially of therapeutic interest for the treatment of tumors that are inherently refractory, or have become resistant, to classical antifolates as a result of decreased expression of the enzyme folylpolyglutamate synthetase. An interesting class of water-soluble nonpolyglutamatable
Steven M Horwitz et al.
Blood, 119(18), 4115-4122 (2012-03-08)
Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with high affinity for reduced folate carrier-1. A dose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that
Sara C Hyoun et al.
Birth defects research. Part A, Clinical and molecular teratology, 94(4), 187-207 (2012-03-22)
Methotrexate and aminopterin are folic acid antagonists that inhibit dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synthesis. Methotrexate has been used for the treatment of malignancy, rheumatic disorders, and psoriasis and termination
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门